Vaxcyte, Inc. (PCVX): EBITDA
-$907.28M
Year ended 2025-12-31
-$1.15B
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$907.28M | n/m | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | -$562.54M | n/m | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | -$464.88M | n/m | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | -$229.42M | n/c | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | -$101.87M | n/m | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | -$88.18M | n/m | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | -$52.92M | n/m | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | -$34.50M | n/a | 2021-03-29, From 2018-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Vaxcyte, Inc. (PCVX) | 2025-12-31 | -$907.28M | n/m |
| Repligen Corp (RGEN) | 2025-12-31 | $133.91M | +287.5% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $901.25M | +42.3% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $349.25M | +64.6% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $480.39M | -14.5% |
| Revolution Medicines, Inc. (RVMD) | 2025-12-31 | -$1.17B | n/m |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | -$645.09M | n/m |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | -$341.09M | n/m |
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | -$361.40M | n/m |
Compare PCVX, RGEN, EXEL, TECH side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗